BRAF and melanoma: Panobinostat restored BRAF inhibitor sensitivity in BRAF-mutant melanoma cells with acquired vemurafenib resistance by suppressing PI3K signaling and c-Myc, which was accompanied by the induction of pro-apoptotic BIM and NOXA [Table 2][90].